Olaparib

奥拉帕利

Report date: 2026/05/16 20:00:17
NMEFirst In Class

Base Information

Drug NameOlaparib
Drug Alias Name奥拉帕尼派力伯Lynparza利普卓KU-0059436 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) Polymerase 3 inhibitorsPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) Polymerase 3Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsUveal melanomaEsophageal adenocarcinomaMetastatic breast cancer +[71] 
Global Approved IndicationsOvarian Neoplasms
Approved Indications in ChinaOvarian Neoplasms
Original Approved Country/TerritoryEU
Original Approved Date2014/12/16
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesSandozKudos Pharmaceuticals LtdIstituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST SRL +[24] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity of Texas Southwestern Medical CenterYale University +[13] 
Active IndicationsMetastatic breast cancerLow-grade GliomaSolid tumours +[57] 
Inactive IndicationsUveal melanomaEsophageal adenocarcinomaSkin Melanoma +[14] 

Other Information

ATC CodeL01XK01
Related LinksWikipediaDrugBankKEGG